Market Closed -
Nasdaq
04:00:00 2024-05-17 pm EDT
|
5-day change
|
1st Jan Change
|
7.04
USD
|
-1.12%
|
|
-27.79%
|
-37.25%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
129.1
|
192.3
|
114.4
|
252.1
|
302.9
|
192.3
|
-
|
-
|
Enterprise Value (EV)
1 |
129.1
|
192.3
|
114.4
|
252.1
|
302.9
|
192.3
|
192.3
|
192.3
|
P/E ratio
|
-10.1
x
|
-9.8
x
|
-6.57
x
|
-10.7
x
|
-18.7
x
|
17.1
x
|
12
x
|
3.88
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
1,131
x
|
-
|
164
x
|
14.3
x
|
3.05
x
|
2.88
x
|
2.03
x
|
EV / Revenue
|
-
|
1,131
x
|
-
|
164
x
|
14.3
x
|
3.05
x
|
2.88
x
|
2.03
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
7.92
x
|
4.85
x
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-17.7
x
|
11.7
x
|
14.4
x
|
42.1
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-5.66%
|
8.53%
|
6.95%
|
2.37%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
19,896
|
25,810
|
26,007
|
26,261
|
26,994
|
27,322
|
-
|
-
|
Reference price
2 |
6.490
|
7.450
|
4.400
|
9.600
|
11.22
|
7.040
|
7.040
|
7.040
|
Announcement Date
|
2/14/20
|
3/30/21
|
2/28/22
|
3/29/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.17
|
-
|
1.535
|
21.25
|
63.08
|
66.72
|
94.55
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
24.3
|
39.7
|
-
|
EBIT
1 |
-13.01
|
-17.88
|
-17.22
|
-22.59
|
-12.77
|
14.32
|
18.18
|
51.09
|
Operating Margin
|
-
|
-10,520.59%
|
-
|
-1,471.6%
|
-60.09%
|
22.7%
|
27.25%
|
54.04%
|
Earnings before Tax (EBT)
1 |
-12.78
|
-18.11
|
-17.35
|
-23.71
|
-12.77
|
10.45
|
12.89
|
45.57
|
Net income
1 |
-12.78
|
-18.11
|
-17.35
|
-23.71
|
-16.04
|
11.94
|
16.28
|
49.45
|
Net margin
|
-
|
-10,652.35%
|
-
|
-1,544.89%
|
-75.5%
|
18.93%
|
24.4%
|
52.3%
|
EPS
2 |
-0.6400
|
-0.7600
|
-0.6700
|
-0.9000
|
-0.6000
|
0.4117
|
0.5867
|
1.813
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-17.14
|
16.4
|
13.36
|
4.567
|
FCF margin
|
-
|
-
|
-
|
-
|
-80.67%
|
26%
|
20.03%
|
4.83%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
67.49%
|
33.66%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
137.33%
|
82.08%
|
9.24%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/14/20
|
3/30/21
|
2/28/22
|
3/29/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
1.535
|
1.677
|
3.325
|
6.515
|
9.735
|
25.38
|
11.55
|
12.5
|
12.98
|
16.53
|
16.07
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.4
|
3
|
5.5
|
15
|
7.3
|
EBIT
1 |
-4.207
|
-3.546
|
-5.009
|
-7.899
|
-6.135
|
-5.27
|
-4.666
|
-1.017
|
-1.818
|
13.74
|
0.3242
|
1.388
|
1.283
|
4.958
|
1.82
|
Operating Margin
|
-
|
-
|
-
|
-
|
-399.67%
|
-314.25%
|
-140.33%
|
-15.61%
|
-18.67%
|
54.16%
|
2.81%
|
11.1%
|
9.88%
|
30%
|
11.33%
|
Earnings before Tax (EBT)
1 |
-4.427
|
-3.696
|
-5.072
|
-8.089
|
-6.857
|
-6.052
|
-5.444
|
-1.867
|
-1.818
|
12.84
|
-0.0604
|
0.456
|
0.0632
|
4.096
|
1.008
|
Net income
1 |
-4.427
|
-3.696
|
-5.072
|
-8.089
|
-6.857
|
-6.052
|
-5.444
|
-1.867
|
-2.682
|
12.84
|
-0.2453
|
0.8503
|
0.8657
|
3.696
|
0.808
|
Net margin
|
-
|
-
|
-
|
-
|
-446.71%
|
-360.88%
|
-163.73%
|
-28.66%
|
-27.55%
|
50.59%
|
-2.12%
|
6.8%
|
6.67%
|
22.36%
|
5.03%
|
EPS
2 |
-0.1800
|
-0.1400
|
-0.1900
|
-0.3100
|
-0.2600
|
-0.2300
|
-0.2100
|
-0.0700
|
-0.1000
|
0.4100
|
-0.0100
|
0.0300
|
0.0283
|
0.1250
|
0.1025
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/12/22
|
8/12/22
|
11/11/22
|
3/29/23
|
5/11/23
|
8/3/23
|
11/6/23
|
3/21/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-17.1
|
16.4
|
13.4
|
4.57
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/14/20
|
3/30/21
|
2/28/22
|
3/29/23
|
3/21/24
|
-
|
-
|
-
|
Last Close Price
7.04
USD Average target price
16.83
USD Spread / Average Target +139.11% Consensus |
1st Jan change
|
Capi.
|
---|
| -37.25% | 192M | | +9.42% | 115B | | +11.84% | 106B | | -1.05% | 21.96B | | -14.15% | 21.87B | | -5.29% | 19.21B | | -4.16% | 18.08B | | -38.29% | 17.71B | | +7.99% | 14.32B | | +36.24% | 12.42B |
Bio Therapeutic Drugs
|